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Abstract: Antimicrobial resistance is a global health issue in the developing countries. This study was carried out to evaluate 
the impact of Mr. Trivedi’s biofield energy treatment on multidrug resistant (MDR) clinical lab isolates (LSs) of 
Staphylococcus species viz. Staphylococcus haemolyticus (LS 18), Staphylococcus epidermidis (LS 21), and Staphylococcus 
aureus (LS 30). Each strain was divided into the two groups i.e. control and treated. The control and treated groups were 
analyzed for the antimicrobial susceptibility pattern, minimum inhibitory concentration (MIC), biochemical analysis and 
biotype number using MicroScan Walk-Away
®
 system. The analysis was done on day 10 after biofield treatment and compared 
with the control group. The sensitivity of erythromycin was improved from resistant to susceptible, while levofloxacin 
sensitivity was also improved from intermediate to susceptible in LS 21 isolate. The MIC results showed a decrease in the 
concentrations of ceftriaxone, erythromycin, imipenem, and levofloxacin antimicrobials in LS 21 as compared to the control. 
Linezolid and vancomycin also showed decrease in MIC as compared to the control in LS 30. Overall, 20.69% antimicrobials 
showed decrease in MIC value out of the tested twenty-nine after biofield treatment in Staphylococcus species. The 
biochemical study showed a 25% alteration in biochemical reactions as compared to the control. A significant change was 
reported in biotype numbers for all the three strains of MDR Staphylococcus species after biofield treatment as compared to the 
respective control group. On the basis of changed biotype number (306366) after biofield treatment in LS 18, the new 
organism was identified as Staphylococcus simulans with respect to the control species i.e. Staphylococcus haemolyticus 
(302302). The control group of S. epidermidis and S. aureus showed biotype number as 303064 and 757153 respectively. After 
biofield treatment, LS 21 and LS 30 isolates showed altered biotype number as 307064 and 317153 respectively. Overall, 
results conclude that biofield treatment could be used as complementary and alternative treatment strategy against multidrug 
resistant strains of Staphylococcus species with improved sensitivity and reduced MIC values of antimicrobial. 
Keywords: Staphylococcus haemolyticus, Staphylococcus epidermidis, Staphylococcus aureus, Biofield Energy Treatment, 
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1. Introduction 
Staphylococci are members of the family 
Staphylococcaceae. They are Gram-positive, catalase-
positive and appear as isolated or in irregular grape-like 
clusters. The classification in this family is based on the 
production of coagulase [1]. The genus Staphylococcus 
represents a broad family of species and subspecies, which 
are widely distributed in nature and consists of approximately 
45 species. The skin and mucosal membranes are the main 
habitats of the human infections. Staphylococci usually 
maintain the symbiotic relationship with host followed by 
crossing the cutaneous barrier and may reach other tissues 
and proliferate [2]. Staphylococcus haemolyticus (S. 
haemolyticus) is the second most common coagulase-
negative staphylococci in the human blood, and is associated 
with bacteremia, skin or soft tissue infections, prosthetic join 
infections, or meningitis [3]. S. haemolyticus and 
Staphylococcus lugdunensis recently reported to have 
association with native valve endocarditis [4]. 
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Staphylococcus epidermidis (S. epidermidis) being the most 
prevalent species on the skin causing different central line-
associated bloodstream infections [5]. S. epidermidis is 
regarded as the commensal microorganism on the human 
skin which is mostly associated with the nosocomial 
infections [6]. Staphylococcus aureus (S. aureus) is classified 
as the major serious human pathogen causing infections 
worldwide, however the other strains of Staphylococcus 
coagulase negative cocci have recently reported to the cause 
serious human infections [7]. Ten major and basic causes of 
death worldwide are due to the nosocomial blood infections 
by pathogenic clinical isolates of S. aureus [8]. S. aureus 
produces toxins that cause various disturbances of the 
immune system [9]. Increased resistance among the different 
pathogenic strains of Staphylococcus species against broad 
spectrum antibiotics is the major health problem, which 
limits the treatment options in front of the physicians. 
Alternative treatment approach to alter the sensitivity profile 
of antimicrobials using biofield treatment on multidrug 
resistant (MDR) microorganism is recently reported [10, 11]. 
Biofield is the name given to the electromagnetic field that 
permeates and surrounds the living organisms. It is the 
scientifically preferred term for the biologically produced 
electromagnetic and subtle energy field that provides 
regulatory and communication functions within the 
organism. In spite of several study reports of the 
effectiveness of the biofield healing therapies [12], there are 
very few well-controlled and peer-reviewed experimental 
studies on pathogenic microorganisms. The biofield energy 
can be monitored by using electromyography (EMG), 
electrocardiography (ECG) and electroencephalogram (EEG) 
[13]. Mr. Trivedi has the ability to harness the energy from 
environment or universe and can transmit into any living or 
nonliving object(s) around the Universe. The objects always 
receive the energy and responding into useful way via 
biofield energy and Mr. Trivedi’s unique biofield energy 
treatment is also known as The Trivedi Effect
®
. Mr. Trivedi’s 
biofield treatment was extensively studied in different fields 
such as in material science [14-16], agricultural science [17-
19], and in biotechnology [20]. Further, the biofield treatment 
has considerably altered the susceptibility of antimicrobials 
and biotype of microbes [10, 11, 21]. By considering the 
significant reports on the biofield treatment, the present work 
was designed to evaluate the influence of biofield energy 
treatment on MDR strains of Staphylococcus species (S. 
haemolyticus, S. epidermidis and S. aureus) with respect to 
antibiogram typing, biochemical reaction pattern, followed 
by biotyping. 
2. Materials and Methods 
2.1. Experimental Design and Bacterial Isolates 
MDR clinical lab isolates (LSs) of S. haemolyticus (LS 
18), S. epidermidis (LS 21) and S. aureus (LS 30) were 
obtained from stored stock cultures in Microbiology Lab, 
Hinduja Hospital, Mumbai. Each MDR strains of 
Staphylococcus species was divided into two groups i.e. 
control and treatment. 
2.2. Biofield Treatment Strategy 
Treatment groups of each strain, in sealed pack were 
handed over to Mr. Trivedi for biofield treatment under 
laboratory conditions. Mr. Trivedi provided the treatment 
through his energy transmission process to the treated groups 
without touching the samples. The biofield treated samples 
were returned in the similar sealed condition and analyzed on 
day 10 using the standard protocols. The following 
parameters like antimicrobial susceptibility, minimum 
inhibitory concentration (MIC), biochemical reactions, and 
biotype number were measured using MicroScan Walk-
Away
®
 automated system (Dade Behring Inc., USA). All 
antimicrobials and biochemicals were procured from Sigma 
Aldrich, USA. 
2.3. Evaluation of Antimicrobial Susceptibility Assay 
The tests carried out on MicroScan were miniaturized of 
the broth dilution susceptibility tests that have been 
dehydrated. Briefly, the standardized suspensions of each 
strain were inoculated, rehydrated, and then subjected to 
incubation for 16 hour at 35°C. The detailed experimental 
procedures and conditions were followed as per the 
manufacturer's instructions. Antimicrobial susceptibility 
patterns of MDR strains of Staphylococcus species (LS 18, 
LS 21, and LS 30) were studied using MicroScan Walk-
Away
® 
using (Dade Behring Inc., West Sacramento, CA, 
USA) using Positive Breakpoint Combo 20 (PBPC 20) panel 
as per the clinical and laboratory standards institute (CLSI) 
guidelines. The antimicrobial susceptibility pattern (S: 
Susceptible, I: Intermediate, R: Resistant, and BLAC: β-
lactamase positive) and MIC values were determined by 
observing the lowest antimicrobial concentration showing 
growth inhibition [22]. 
2.4. Biochemical Study 
Biochemical studies of each MDR strains of 
Staphylococcus species were determined by MicroScan 
Walk-Away
®
 using PBPC 20 panel system, it interprets the 
microbe biochemical results with the use of a photometric or 
fluorogenic reader. On the basis of nature of bacilli (Gram-
negative or Gram-positive), it generates computerized reports 
using conventional panels, which utilizes the photometric 
reader and provide identification results. Before commencing 
the experiment, the NBPC 30 panel was first incubated and 
read on the MicroScan Walkaway system. After completion 
of reading on the Walkaway system, the PBPC 20 panel was 
removed from system and read on the Biomic system within 
1 hour. MicroScan Walk-Away instrument consist of a 
database associated with collective information, which was 
required to identify the group, genera, or species of the 
family. Detailed experimental procedure was followed as per 
manufacturer-recommended instructions. Biochemicals used 
in the study were arabinose, arginine, bacillosamine, bile 
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esculin, β-lactamases, crystal violet, indoxyl phosphatase, 
inulin, acidification lactose, mannitol, mannose, micrococcus 
screen, sodium chloride, nitrate, novobiocin, optochin, p-
nitro phenyl β-D-glucuronide, p-nitro phenyl β-D-
galactopyranoside, phosphatase, pyruvate, pyrolidonyl 
arylamidase, raffinose, rambose, sorbitol, thymidine free 
growth, acidification trehalose, urea, and Voges-Proskauer 
[22]. 
2.5. Identification by Biotype Number 
The biotype number of each MDR strains of 
Staphylococcus species in control and treated sample was 
determined followed by identification of microorganism by 
MicroScan Walk-Away
®
 processed panel data report with the 
help of biochemical reaction data [22]. 
3. Results and Discussion 
3.1. Antimicrobial Susceptibility Study 
Antimicrobial sensitivity pattern and MIC values of 
control and biofield treated MDR strains of Staphylococcus 
species are summarized in Table 1 and 2, respectively. 
Altered sensitivity of tested antimicrobials were observed on 
day 10 after biofield treatment, and compared with respect to 
the control. Antimicrobial sensitivity after biofield treatment 
in case of S. haemolyticus (LS 18) strain showed no change 
in twenty-seven tested antimicrobials with respect to the 
control. Erythromycin sensitivity was improved i.e. resistant 
to susceptible, while levofloxacin sensitivity was also 
improved from intermediate to susceptible in biofield treated 
S. epidermidis (LS 21). Now, erythromycin and levofloxacin 
are active against biofield treated S. epidermidis. Most of the 
isolates of S. epidermidis had been observed for multidrug 
resistant against penicillin, oxacillin, gentamycin, 
erythromycin, and doxycycline. Resistant pattern of most of 
the antimicrobials in control group is well supported with 
literature data [23]. Rest of the tested antimicrobials did not 
show any alteration in antimicrobial sensitivity in LS 18, LS 
21 and LS 30. MIC results showed an alteration of 20.69% 
among twenty-nine tested antimicrobials. The MIC value of 
erythromycin after biofield treatment on S. epidermidis 
showed eight-fold decrease (i.e. >4 to ≤0.5 µg/mL) in 
concentration required to inhibit the visible growth of 
microorganism with respect to the control. Ceftriaxone also 
showed four fold decrease in MIC value after biofield 
treatment in LS 21 with respect to control i.e. 32 to ≤8 
µg/mL. Imipenem (>8 to ≤4 µg/mL) and levofloxacin (4 to 
≤2 µg/mL) showed two-folds decrease in MIC value in 
biofield treated LS 21 as compared to control. Biofield 
treatment in S. aureus (LS 30) also showed two-fold decrease 
in MIC value in case of linezolid (>4 to ≤2 µg/mL)  and 
vancomycin (4 to ≤2 µg/mL) as compared to respective 
control. Remaining antimicrobials did not show any 
alteration in MIC values in LS 21 and LS 30. Staphylococcus 
haemolyticus (LS 18) did not show any alteration with 
respect to antimicrobial susceptibility pattern and MIC value 
among tested antimicrobials (Table 2). 
Table 1. Effect of biofield treatment on multidrug resistant lab isolates of Staphylococcus spp. to antimicrobial susceptibility. 
S. No. Antimicrobial 
LS 18 LS 21 LS 30 
C T C T C T 
1. Amoxicillin/k-clavulanate R R R R R R 
2. Ampicillin/sulbactam R R R R R R 
3. Ampicillin BLAC BLAC BLAC BLAC BLAC BLAC 
4. Azithromycin R R R R R R 
5. Cefazolin R R R R R R 
6. Cefepime R R R R R R 
7. Cefotaxime R R R R R R 
8. Ceftriaxone R R R R R R 
9. Cephalothin R R R R R R 
10. Chloramphenicol S S S S R R 
11. Ciprofloxacin R R R R R R 
12. Clindamycin R R R R R R 
13. Erythromycin R R R S R R 
14. Gatifloxacin I I S S R R 
15. Gentamicin R R R R R R 
16. Imipenem R R R R R R 
17. Levofloxacin R R I S R R 
18. Linezolid S S S S - S 
19. Moxifloxacin S S S S R R 
20. Ofloxacin R R I I R R 
21. Oxacillin R R R R R R 
22. Penicillin BLAC BLAC BLAC BLAC BLAC BLAC 
23. Rifampin R R R R R R 
24. Synercid S S S S S S 
25. Tetracycline R R S S R R 
26. Trimethoprim/sulfamethoxazole R R R R R R 
27. Vancomycin S S S S S S 
C: Control; T: Treatment; LS: Lab Isolate; R: Resistant; I: Intermediate; S: Susceptible; LS 18: S. haemolyticus; LS 21: S. epidermidis; LS 30: S. aureus; 
BLAC: β-lactamase positive; -: Not tested. 
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Table 2. Minimum inhibitory concentration (MIC) of tested antimicrobials for multidrug resistant lab isolates of Staphylococcus spp. 
S. No. Antimicrobial 
LS 18 LS 21 LS 30 
C T C T C T 
1. Amoxicillin/k-clavulanate >4/2 >4/2 ≤4/2 ≤4/2 >4/2 >4/2 
2. Ampicillin/sulbactam 16/8 16/8 ≤8/4 ≤8/4 16/8 16/8 
3. Ampicillin >8 >8 8 8 >8 >8 
4. Azithromycin >4 >4 >4 >4 >4 >4 
5. Cefazolin >16 >16 ≤8 ≤8 >16 >16 
6. Cefepime >16 >16 ≤8 ≤8 >16 >16 
7. Cefotaxime >32 >32 ≤8 ≤8 >32 >32 
8. Ceftriaxone >32 >32 32 ≤8 >32 >32 
9. Cephalothin >16 >16 ≤8 ≤8 >16 >16 
10. Chloramphenicol ≤8 ≤8 ≤8 ≤8 >16 >16 
11. Ciprofloxacin >2 >2 >2 >2 >2 >2 
12. Clindamycin >2 >2 >2 >2 >2 >2 
13. Erythromycin >4 >4 >4 ≤0.5 >4 >4 
14. Gatifloxacin 4 4 ≤2 ≤2 >4 >4 
15. Gentamicin >8 >8 >8 >8 >8 >8 
16. Imipenem >8 >8 >8 ≤4 >8 >8 
17. Levofloxacin >4 >4 4 ≤2 >4 >4 
18. Linezolid ≤2 ≤2 ≤2 ≤2 >4 ≤2 
19. Moxifloxacin ≤2 ≤2 ≤2 ≤2 >4 >4 
20. Nitrofurantoin ≤32 ≤32 ≤32 ≤32 ≤32 ≤32 
21. Norfloxacin >8 >8 >8 >8 >8 >8 
22. Ofloxacin >4 >4 4 4 >4 >4 
23. Oxacillin >2 >2 >2 >2 >2 >2 
24. Penicillin >8 >8 8 8 >8 >8 
25. Rifampin >2 >2 >2 >2 >2 >2 
26. Synercid ≤1 ≤1 ≤1 ≤1 ≤1 ≤1 
27. Tetracycline >8 >8 ≤4 ≤4 >8 >8 
28. Trimethoprim/sulfamethoxazole >2/38 >2/38 >2/38 >2/38 >2/38 >2/38 
29. Vancomycin ≤2 ≤2 ≤2 ≤2 4 ≤2 
MIC values are presented in µg/mL; C: Control; T: Treatment; LS: Lab Isolate; LS 18: S. haemolyticus; LS 21: S. epidermidis; LS 30: S. aureus. 
3.2. Identification by Biochemical and Biotype Number 
Study 
Biochemical study results of control and biofield treated 
strains of Staphylococcus species are summarized in Table 3 
and Table 4. Results showed that overall 25% change in 
tested biochemical reactions among three tested MDR strains 
of Staphylococcus species as compared to respective control. 
Rambose changed from (+) positive to (-) negative reaction 
with respect to control in S. haemolyticus (LS 18). However, 
biochemicals such as acidification lactose, glycosidase, urea, 
and Voges-Proskauer changed from (-) negative to (+) 
positive reaction in LS 18 as compared to control. Only one 
biochemical i.e. Voges-Proskauer showed (-) negative to (+) 
positive reaction in S. epidermidis (LS 21) as compared to 
control. Basic characteristics of S. aureus are colony 
pigment, free coagulase, clumping factor, protein A, heat-
stable nuclease, and acid production from mannitol. Crystal 
violet is the characteristic positive feature of S. aureus, but 
after biofield treatment in S. aureus (LS 30), it was changed 
from (+) positive to (-) negative reaction. Novobiocin 
changed from (+) positive to (-) negative reaction in LS 30 
with respect to control. Rest of the biochemical reactions did 
not show any alteration after biofield treatment. 
Biochemical reactions of control MDR strains of 
Staphylococcus species were well supported with literature 
data [28, 29]. Based on the biochemical results, significant 
alteration in biotype number was observed in all three strains 
i.e. LS 18, LS 21, and LS 30 as compared to respective 
control. Biofield treatment in LS 18 showed an alteration in 
biotype number (306366) with the identification of new 
organism as Staphylococcus simulans on day 10 with respect 
to control (302302) (Table 4). Control group of S. 
epidermidis (LS 21) and S. aureus (LS 30) strains showed 
biotype number as 303064 and 757153 respectively. After 
biofield treatment LS 21 and LS 30 showed altered biotype 
number as 307064 and 317153 respectively (Table 4). 
Biofield treatment was recently used on pathogenic microbes 
to alter the biotype number on the basis of changed 
biochemical reactions [11, 21]. 
Biofield energy treatment as an alternate and 
complementary medicine, now included in subcategory of 
energy therapies by National Center for Complementary and 
Alternative Medicine/National Institute of Health 
(NCCAM/NIH) [30]. Mr. Trivedi’s biofield treatment on 
pathogenic microbes was extensively studied and observed 
for alteration in the antimicrobial sensitivity pattern, 
biochemical reactions, and biotype number [10, 11]. Biofield 
treatment might involve alteration at genetic level and/or 
enzymatic level, which could hamper the drug ligand-
receptor/protein interactions. Hence, a cascade of intra-
cellular signals may be initiated, accelerated or inhibited 
 American Journal of Life Sciences 2015; 3(5): 369-374 373 
 
[31]. The overall study data showed that, biofield treatment 
on MDR strains of Staphylococcus species improved the 
sensitivity pattern and decrease in MIC value of 20.69% 
tested antimicrobial, alter biochemical reactions, and biotype 
number. 
Table 3. Effect of biofield treatment on multidrug resistant lab isolates of Staphylococcus spp.to the vital processes occurring in living organisms. 
S. No. Code Biochemical 
LS 18 LS 21 LS 30 
C T C T C T 
1. ARA Arabinose - - - - - - 
2. ARG Arginine + + - - + + 
3. BAC Bacillosamine + + + + + + 
4. BE Bile esculin - - - - - - 
5. BL β-lactamases + + + + + + 
6. CV Crystal violet - - - - + - 
7. IDX Indoxyl phosphatase - - - - + + 
8. INU Inulin - - - - - - 
9. LAC Acidification lactose - + + + - - 
10. MAN Mannitol - - - - + + 
11. MNS Mannose - - - - + + 
12. MS Micrococcus screen + + + + + + 
13. NACL Sodium chloride + + + + + + 
14. NIT Nitrate + + + + + + 
15. NOV Novobiocin - - - - + - 
16. OPT Optochin + + + + + + 
17. PGR Glycosidase* - - - - - - 
18. PGT Glycosidase# - + + + + + 
19. PHO Phosphatase - - + + + + 
20. PRV Pyruvate - - - - - - 
21. PYR Pyrolidonyl arylamidase + + - - - - 
22. RAF Raffinose - - - - - - 
23. RBS Rambose + - - - - - 
24. SOR Sorbitol - - - - - - 
25. TFG Thymidine free growth + + + + + + 
26. TRE Acidification trehalose + + - - + + 
27. URE Urea - + + + - - 
28. VP Voges-Proskauer - + - + + + 
C: Control; T: Treatment; LS: Lab Isolate; LS 18: S. haemolyticus; LS 21: S. epidermidis; LS 30: S. aureus; -: negative; +: positive; *PGR: p-nitro phenyl β-D- 
glucuronide; #PGT: p-nitro phenyl β-D-galactopyranoside. 
Table 4. Effect of biofield treatment on multidrug resistant lab isolates of 
Staphylococcus spp.to distinguishing feature of the genotype. 
Isolate Group Biotype Number Organism Identification 
LS 18 
C 302302 Staphylococcus haemolyticus 
T 306366 Staphylococcus simulans 
LS 21 
C 303064 Staphylococcus epidermidis 
T 307064 Staphylococcus epidermidis 
LS 30 
C 757153 Staphylococcus aureus 
T 317153 Staphylococcus aureus 
C: Control; T: Treatment; LS: Lab Isolate; LS 18: S. haemolyticus; LS 21: S. 
epidermidis; LS 30: S. aureus 
4. Conclusions 
Overall results suggested the impact of biofield treatment 
on Staphylococcus species. Antimicrobial sensitivity results 
in improved sensitivity pattern of erythromycin, with eight-
fold decrease in MIC value (i.e. >4 to ≤0.5 µg/mL), while, 
levofloxacin was also reported with improved sensitivity 
pattern with improved MIC value (4 to ≤2 µg/mL) in biofield 
treated S. epidermidis. Biofield treatment on Staphylococcus 
species showed altered effect on 25% tested biochemicals 
and biotype numbers. A significant change in biotype number 
(306366) on the basis of altered biochemical reactions as 
compared to control (302302). Altered biotype number 
results in identification of new organism as Staphylococcus 
simulans with respect to control species as S. haemolyticus in 
LS 18 after biofield treatment. Based on the results, Mr. 
Trivedi’s biofield energy treatment could be applied to 
improve the sensitivity pattern of antimicrobials, against 
multidrug resistance strains of Staphylococcus species. 
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